ARTICLE | Company News
Lorus cancer news
October 28, 2013 7:00 AM UTC
Lorus announced in its first quarter earnings for the fiscal year ending May 31, 2014, that the company has begun a review of strategic alternatives to secure long-term financial and operational sustainability. Options include a merger, sale, strategic partnerships or alliances and equity or debt financings. Lorus' LOR-253, a small molecule optimized to increase expression of Kruppel-like factor 4 ( KLF4; EZF), is in Phase I testing to treat solid tumors. ...